These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31732842)

  • 21. Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma.
    Falegan OS; Ball MW; Shaykhutdinov RA; Pieroraio PM; Farshidfar F; Vogel HJ; Allaf ME; Hyndman ME
    Metabolites; 2017 Feb; 7(1):. PubMed ID: 28165361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SELDI-TOF-MS-based serum proteomic screening in combination with CT scan distinguishes renal cell carcinoma from benign renal tumors and healthy persons.
    Xu G; Xiang CQ; Lu Y; Wang WJ; Kang XN; Liao P; Ding Q; Zhang YF
    Technol Cancer Res Treat; 2009 Jun; 8(3):225-30. PubMed ID: 19445540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients.
    Popławski P; Tohge T; Bogusławska J; Rybicka B; Tański Z; Treviño V; Fernie AR; Piekiełko-Witkowska A
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):744-752. PubMed ID: 28012969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.
    Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY
    Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.
    Monteiro MS; Barros AS; Pinto J; Carvalho M; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Guedes de Pinho P
    Sci Rep; 2016 Nov; 6():37275. PubMed ID: 27857216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma.
    Mytsyk Y; Dosenko V; Borys Y; Kucher A; Gazdikova K; Busselberg D; Caprnda M; Kruzliak P; Farooqi AA; Lubov M
    Int Urol Nephrol; 2018 May; 50(5):851-859. PubMed ID: 29549624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathway analysis of kidney cancer using proteomics and metabolic profiling.
    Perroud B; Lee J; Valkova N; Dhirapong A; Lin PY; Fiehn O; Kültz D; Weiss RH
    Mol Cancer; 2006 Nov; 5():64. PubMed ID: 17123452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential protein profiling of renal cell carcinoma urinary exosomes.
    Raimondo F; Morosi L; Corbetta S; Chinello C; Brambilla P; Della Mina P; Villa A; Albo G; Battaglia C; Bosari S; Magni F; Pitto M
    Mol Biosyst; 2013 Jun; 9(6):1220-33. PubMed ID: 23511837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Machine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics.
    Bifarin OO; Gaul DA; Sah S; Arnold RS; Ogan K; Master VA; Roberts DL; Bergquist SH; Petros JA; Fernández FM; Edison AS
    J Proteome Res; 2021 Jul; 20(7):3629-3641. PubMed ID: 34161092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
    Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
    Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases.
    Gao H; Dong B; Jia J; Zhu H; Diao C; Yan Z; Huang Y; Li X
    J Cancer Res Clin Oncol; 2012 May; 138(5):753-61. PubMed ID: 22258851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.
    Wettersten HI; Hakimi AA; Morin D; Bianchi C; Johnstone ME; Donohoe DR; Trott JF; Aboud OA; Stirdivant S; Neri B; Wolfert R; Stewart B; Perego R; Hsieh JJ; Weiss RH
    Cancer Res; 2015 Jun; 75(12):2541-52. PubMed ID: 25952651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia.
    Tickoo SK; dePeralta-Venturina MN; Harik LR; Worcester HD; Salama ME; Young AN; Moch H; Amin MB
    Am J Surg Pathol; 2006 Feb; 30(2):141-53. PubMed ID: 16434887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer.
    Morrissey JJ; Mobley J; Figenshau RS; Vetter J; Bhayani S; Kharasch ED
    Mayo Clin Proc; 2015 Jan; 90(1):35-42. PubMed ID: 25572193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis.
    Ganti S; Taylor SL; Abu Aboud O; Yang J; Evans C; Osier MV; Alexander DC; Kim K; Weiss RH
    Cancer Res; 2012 Jul; 72(14):3471-9. PubMed ID: 22628425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.
    Morozumi K; Kawasaki Y; Maekawa M; Takasaki S; Sato T; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
    Cancer Sci; 2022 Jan; 113(1):182-194. PubMed ID: 34710258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Urinary metabolomics study of renal cell carcinoma based on gas chromatography-mass spectrometry].
    Zhang L; Li L; Kong H; Zeng F
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 May; 35(5):763-6. PubMed ID: 26018279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the metabolomic profile of renal cell carcinoma by high resolution magic angle spinning proton magnetic resonance spectroscopy.
    Huynh MJ; Gusev A; Palmas F; Vandergrift L; Berker Y; Wu CL; Wu S; Cheng LL; Feldman AS
    Urol Oncol; 2023 Nov; 41(11):459.e9-459.e16. PubMed ID: 37863744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic profiling reveals key metabolic features of renal cell carcinoma.
    Catchpole G; Platzer A; Weikert C; Kempkensteffen C; Johannsen M; Krause H; Jung K; Miller K; Willmitzer L; Selbig J; Weikert S
    J Cell Mol Med; 2011 Jan; 15(1):109-18. PubMed ID: 19845817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.